Thermo Fisher and Genedata Enter Mass Spec Alliance

By Allison Proffitt

July 14, 2008Thermo Fisher Scientific and Genedata have integrated Thermo’s mass spectrometry (MS) instrument with Genedata’s suite of software solutions to efficiently process and analyze large volumes of high-quality MS data. 

Both companies will continue to sell and support their own products, but through a co-marketing agreement, Thermo and Genedata will offer customers both the mass spec instrumentation and the pre-processing and data analysis.

Mass spec presents a problem, Jens Hoefkens, Genedata’s managing director told Bio-IT World. It enables “customers to produce vast quantities of data that are hard to analyze… Genedata has been processing large quantities of data and developing data mining tools to make sense of those data for a number of years now. And that’s why we think this is a terrific fit for us to work together with Thermo.”

Thermo and Genedata believe that combining the Thermo Scientific MS systems with Genedata software solutions will enable researchers to enhance small-molecule biomarker detection with an "end-to-end" system that encompasses complete scientific workflows.

“If you think about this data when they come off the instrument, they do require some pre-processing,” says Hoefkens. “So you start out with hundreds of gigabytes of data you have to do background subtraction, noise removal, you have to correct for problems with alignment, things that are incidentally inherent in the technology. We do the pre-processing there, so we take the data off Thermo’s instruments, read their files, and process the data,”

The advantages for the customer are many, Hoefkens believes. “By working together, [Thermo and Genedata] exchange information behind the scenes so we get access to information about file format and changes, upcoming changes that enable us to make sure that the software will always be able to make use of the latest and greatest features in the instrument. At the same time we will of course be able to provide a much tighter integration, so there will be no need for the customer to copy files, transfer files, [or] reformat them so that they can be imported into a software system.”

Genedata’s software isn’t limited to pre-processing. The Expressionist software suite is modular and includes modules for data mining and data analysis. The advantage for customers, says Hoefkens, is “the ability to combine your metabolomics data from the Thermo instrument with, say for example, gene expression data from the Affymetrix platform, and having multiple data streams all ending up in a single data mining platform where you can then do cross omics integration and leverage the different insights you can get from different omics data streams to get more thorough understanding of the biology.”



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .